Medications for Hepatitis C
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hepatitis C.
Found 6 Approved Drugs for Hepatitis C
Sofosbuvir
Brand Names
Sovaldi, Epclusa, Ledipasvir, Vosevi, Harvoni
Sofosbuvir
Brand Names
Sovaldi, Epclusa, Ledipasvir, Vosevi, Harvoni
Form: Pellet, Tablet
Method of administration: Oral
FDA approval date: December 06, 2013
Classification: Hepatitis C Virus NS5A Inhibitor
HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see Dosage and Administration.
Pegasys
Generic Name
PEGinterferon Alfa-2A
Pegasys
Generic Name
PEGinterferon Alfa-2A
Form: Injection
Method of administration: Subcutaneous
FDA approval date: October 16, 2002
Classification: Interferon alpha
PEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C (CHC).
Lamivudine
Brand Names
Cimduo, Combivir, Epzicom, Delstrigo, Dovato, SYMFI, Triumeq, Efavirenz, Abacavir, Epivir
Lamivudine
Brand Names
Cimduo, Combivir, Epzicom, Delstrigo, Dovato, SYMFI, Triumeq, Efavirenz, Abacavir, Epivir
Form: Tablet, Kit, Solution
Method of administration: Oral
FDA approval date: October 04, 2010
Classification: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Efavirenz, lamivudine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg. Efavirenz, lamivudine and tenofovir disoproxil fumarate tablets are three-drug combination of efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), both nucleo(t)side reverse transcriptase inhibitors and are indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg. ( 1 )
Zepatier
Generic Name
Elbasvir
Zepatier
Generic Name
Elbasvir
Form: Tablet
Method of administration: Oral
FDA approval date: January 28, 2016
Classification: Hepatitis C Virus NS3/4A Protease Inhibitor
ZEPATIER ® is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adult and pediatric patients 12 years of age and older or weighing at least 30 kg. ZEPATIER is indicated for use with ribavirin in certain patient populations [see Dosage and Administration.
Mavyret
Generic Name
Glecaprevir
Mavyret
Generic Name
Glecaprevir
Form: Pellet, Tablet
Method of administration: Oral
FDA approval date: August 03, 2017
Classification: Hepatitis C Virus NS3/4A Protease Inhibitor
MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [see Dosage and Administration.
Showing 1-5 of 6
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances